What question did this study set out to answer?

To compare the efficacy and tolerability of the antiplatelet drug triflusal with aspirin for secondary prevention following acute myocardial infarction.

March 1, 2000European Heart JournalOpen Access

Randomized comparative trial of triflusal and aspirin following acute myocardial infarction

View Full Paper

Ask AI

Bookmark

Why the study?

Does triflusal reduce death, non-fatal myocardial reinfarction, or non-fatal cerebrovascular events compared to aspirin in patients with acute myocardial infarction?

Population

2124 patients randomized within 24 h of acute myocardial infarction symptom onset

Comparison

Triflusal 600 mg once daily for 35 days vs Aspirin 300 mg once daily for 35 days

Design

RCT, Randomized within 24 h of acute myocardial infarction symptom onset…

Follow-up

35 days

Authors

JCJosé María Cruz-FernándezHospital Clínico Universitario Virgen de la Victoria

Discussion

Member takes

Implication

Triflusal matches aspirin's efficacy post-AMI; confirms its viability as an alternative antiplatelet in secondary prevention.

Key Points

To compare the efficacy and tolerability of the antiplatelet drug triflusal with aspirin for secondary prevention following acute myocardial infarction.
Conducted a double-blind, multicenter, sequential design randomized trial across 2,124 validated patients presenting within 24 hours of acute myocardial infarction symptom onset.
Assigned participants to receive either triflusal 600 mg once daily or aspirin 300 mg once daily for 35 days.
Evaluated a primary composite endpoint of death, non-fatal myocardial reinfarction, or non-fatal cerebrovascular events, alongside secondary endpoints including urgent revascularization and bleeding.
The primary composite endpoint showed equivalent efficacy between treatments, supporting the null hypothesis of no difference (OR 0.882, 95% CI 0.634–1.227).
Triflusal significantly reduced non-fatal cerebrovascular events compared to aspirin (OR 0.364, 95% CI 0.146–0.908; P = 0.030), with no significant differences in death (OR 0.816, 95% CI 0.564–1.179; P = 0.278) or reinfarction (OR 1.577, 95% CI 0.873–2.848; P = 0.131).
Central nervous system bleeding episodes occurred significantly less frequently with triflusal than with aspirin (0.27% vs. 0.97%; P = 0.033).

Structured PICO

Does triflusal reduce death, non-fatal myocardial reinfarction, or non-fatal cerebrovascular events compared to aspirin in patients with acute myocardial infarction?

Population

2124 patients randomized within 24 h of acute myocardial infarction symptom onset

Intervention

Triflusal 600 mg once daily for 35 days

Comparator

Aspirin 300 mg once daily for 35 days

Outcome

Composite of death, non-fatal myocardial reinfarction or a non-fatal cerebrovascular eventcomposite

Triflusal demonstrates similar efficacy to aspirin in preventing cardiovascular events after acute myocardial infarction, but with a more favorable safety profile regarding central nervous system bleeding.

Cite This Study

José María Cruz-Fernández (2000) studied this question.

synapsesocial.com/papers/6a736b1d20644e164b4e59d0 https://doi.org/10.1053/euhj.1999.1874

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Randomized comparative trial of triflusal and aspirin following acute myocardial infarction

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Randomized comparative trial of triflusal and aspirin following acute myocardial infarction

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider